OA11227A - Pharmaceutical compositions containing eletriptan hemisulphate and caffeine - Google Patents
Pharmaceutical compositions containing eletriptan hemisulphate and caffeine Download PDFInfo
- Publication number
- OA11227A OA11227A OA9900271A OA9900271A OA11227A OA 11227 A OA11227 A OA 11227A OA 9900271 A OA9900271 A OA 9900271A OA 9900271 A OA9900271 A OA 9900271A OA 11227 A OA11227 A OA 11227A
- Authority
- OA
- OAPI
- Prior art keywords
- composition
- volume
- weight
- présent
- éthanol
- Prior art date
Links
- 229960002472 eletriptan Drugs 0.000 title claims abstract description 49
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 title claims abstract description 42
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 229960001948 caffeine Drugs 0.000 title claims abstract description 21
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 7
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 title claims abstract 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 63
- 239000000203 mixture Substances 0.000 claims description 62
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 230000003078 antioxidant effect Effects 0.000 claims description 8
- 235000006708 antioxidants Nutrition 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 206010059245 Angiopathy Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 206010009094 Chronic paroxysmal hemicrania Diseases 0.000 claims description 2
- 208000006561 Cluster Headache Diseases 0.000 claims description 2
- 206010013654 Drug abuse Diseases 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 206010047700 Vomiting Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 208000007777 paroxysmal Hemicrania Diseases 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- PWVXXGRKLHYWKM-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC(C1=C2)=CNC1=CC=C2CCS(=O)(=O)C1=CC=CC=C1 PWVXXGRKLHYWKM-LJQANCHMSA-N 0.000 description 44
- 235000015165 citric acid Nutrition 0.000 description 18
- 229960004106 citric acid Drugs 0.000 description 18
- 239000000243 solution Substances 0.000 description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 238000009472 formulation Methods 0.000 description 8
- 239000011668 ascorbic acid Substances 0.000 description 7
- 235000010323 ascorbic acid Nutrition 0.000 description 7
- 229960005070 ascorbic acid Drugs 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 235000011121 sodium hydroxide Nutrition 0.000 description 6
- 229940083608 sodium hydroxide Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000003928 nasal cavity Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 210000002850 nasal mucosa Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 230000010224 hepatic metabolism Effects 0.000 description 2
- 150000002990 phenothiazines Chemical class 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 238000013097 stability assessment Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9714081.8A GB9714081D0 (en) | 1997-07-03 | 1997-07-03 | Pharmaceutical compositions |
GBGB9718270.3A GB9718270D0 (en) | 1997-07-03 | 1997-08-28 | Pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
OA11227A true OA11227A (en) | 2003-07-18 |
Family
ID=26311826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA9900271A OA11227A (en) | 1997-07-03 | 1999-12-03 | Pharmaceutical compositions containing eletriptan hemisulphate and caffeine |
Country Status (31)
Country | Link |
---|---|
US (1) | US6166025A (ja) |
EP (1) | EP0999841B1 (ja) |
JP (1) | JP3350061B2 (ja) |
CN (1) | CN1145486C (ja) |
AT (1) | ATE206921T1 (ja) |
AU (1) | AU724728B2 (ja) |
BG (1) | BG103930A (ja) |
BR (1) | BR9810658A (ja) |
CA (1) | CA2292673C (ja) |
DE (1) | DE69802097T2 (ja) |
DK (1) | DK0999841T3 (ja) |
DZ (1) | DZ2549A1 (ja) |
EA (1) | EA002174B1 (ja) |
ES (1) | ES2163291T3 (ja) |
HK (1) | HK1029282A1 (ja) |
HR (1) | HRP990416B1 (ja) |
HU (1) | HUP0004468A3 (ja) |
ID (1) | ID24528A (ja) |
IL (1) | IL133206A0 (ja) |
IS (1) | IS5283A (ja) |
MA (1) | MA26518A1 (ja) |
NO (1) | NO312993B1 (ja) |
NZ (1) | NZ501419A (ja) |
OA (1) | OA11227A (ja) |
PL (1) | PL337803A1 (ja) |
PT (1) | PT999841E (ja) |
SI (1) | SI0999841T1 (ja) |
SK (1) | SK284462B6 (ja) |
TR (1) | TR199903332T2 (ja) |
UY (1) | UY25078A1 (ja) |
WO (1) | WO1999001135A1 (ja) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9816556D0 (en) * | 1998-07-30 | 1998-09-30 | Pfizer Ltd | Therapy |
GB9825988D0 (en) | 1998-11-27 | 1999-01-20 | Pfizer Ltd | Indole derivatives |
GB9922963D0 (en) | 1999-09-28 | 1999-12-01 | Pfizer Ltd | Polymorphic salt |
AU4799700A (en) * | 1999-04-27 | 2000-11-10 | Board Of Regents, The University Of Texas System | A composition and method for treatment of cerebral ischemia |
GB9915231D0 (en) | 1999-06-29 | 1999-09-01 | Pfizer Ltd | Pharmaceutical complex |
IL136961A0 (en) * | 1999-06-30 | 2001-06-14 | Pfizer Prod Inc | 5ht1 receptor agonists, caffeine and either a cox-2 inhibitor or nsaid for the treatment of migraine |
CO5190664A1 (es) * | 1999-06-30 | 2002-08-29 | Pfizer Prod Inc | Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2 |
CO5190678A1 (es) * | 1999-06-30 | 2002-08-29 | Pfizer Prod Inc | Terapia combinada para el tratamiento de la migrana |
GB9923314D0 (en) | 1999-10-01 | 1999-12-08 | Pfizer Ltd | Acylation process |
US6579898B2 (en) * | 2001-03-01 | 2003-06-17 | Pfizer Inc. | Compositions having improved bioavailability |
WO2003020977A2 (en) * | 2001-08-31 | 2003-03-13 | The University Court Of The University Of Glasgow | Nucleotide repeats assay |
US7404489B1 (en) | 2003-03-04 | 2008-07-29 | Qol Medical, Llc | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
US7132549B2 (en) | 2003-05-30 | 2006-11-07 | Pfizer Inc. | Process |
GB0312478D0 (en) * | 2003-05-30 | 2003-07-09 | Pfizer Ltd | Improved process |
GB2407498B (en) * | 2003-10-30 | 2008-06-11 | Cipla Ltd | Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient |
US20080286388A1 (en) * | 2004-10-22 | 2008-11-20 | Shin-Jen Shiao | Pharmaceutical Composition and Non Dependence Coffee Comprising Edible Carboxylic Acid and/or Its Acid Salts and Coffeine |
US8506934B2 (en) | 2005-04-29 | 2013-08-13 | Robert I. Henkin | Methods for detection of biological substances |
US20070111964A1 (en) | 2005-08-17 | 2007-05-17 | Fleming And Company, Pharmaceuticals | Vitamin B12 nasal spray and method of use |
US20070041905A1 (en) * | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
WO2008095136A2 (en) | 2007-01-31 | 2008-08-07 | Henkin Robert I | Methods for detection of biological substances |
FR2926721B1 (fr) * | 2008-01-30 | 2011-07-22 | Philippe Perovitch | Forme galenique pour l'adminsitration par voie trans-muqueuse de triptans |
US8580801B2 (en) | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
JP2012036167A (ja) * | 2010-07-16 | 2012-02-23 | Taisho Pharmaceutical Co Ltd | 内服液剤 |
US8915245B2 (en) * | 2010-10-07 | 2014-12-23 | Vapotherm, Inc. | Nebulizer systems, apparatus and methods for respiratory therapy |
JP5887893B2 (ja) * | 2010-12-10 | 2016-03-16 | 大正製薬株式会社 | 内服液剤 |
JP5887894B2 (ja) * | 2010-12-10 | 2016-03-16 | 大正製薬株式会社 | 内服液剤 |
EP2968204B1 (en) * | 2013-03-15 | 2019-05-15 | Robert I. Henkin | Phosphodiesterase inhibitors for treating taste and smell disorders |
EP3488889A1 (en) | 2013-08-08 | 2019-05-29 | Vapotherm, Inc. | Respiratory therapy condensation adaptor |
NL1040474C2 (en) | 2013-10-31 | 2015-05-04 | Veramed B V | Nasal compositions stimulating ciliary activity. |
WO2015126944A1 (en) | 2014-02-18 | 2015-08-27 | Henkin Robert I | Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell |
JP6097787B2 (ja) * | 2015-06-09 | 2017-03-15 | パル ファーマシューティカル, インコーポレーテッド | 鼻内送達用シアノコバラミン低粘度水性製剤 |
FR3053334B1 (fr) * | 2016-06-30 | 2018-07-27 | L'oreal | Melange liquide contenant du 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one et de compose de xanthine |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9417310D0 (en) * | 1994-08-27 | 1994-10-19 | Pfizer Ltd | Therapeutic agents |
-
1998
- 1998-07-01 AU AU88569/98A patent/AU724728B2/en not_active Ceased
- 1998-07-01 TR TR1999/03332T patent/TR199903332T2/xx unknown
- 1998-07-01 DZ DZ980159A patent/DZ2549A1/xx active
- 1998-07-01 SK SK1828-99A patent/SK284462B6/sk unknown
- 1998-07-01 HU HU0004468A patent/HUP0004468A3/hu unknown
- 1998-07-01 UY UY25078A patent/UY25078A1/es not_active IP Right Cessation
- 1998-07-01 DK DK98940152T patent/DK0999841T3/da active
- 1998-07-01 DE DE69802097T patent/DE69802097T2/de not_active Expired - Fee Related
- 1998-07-01 ES ES98940152T patent/ES2163291T3/es not_active Expired - Lifetime
- 1998-07-01 CA CA002292673A patent/CA2292673C/en not_active Expired - Fee Related
- 1998-07-01 MA MA25150A patent/MA26518A1/fr unknown
- 1998-07-01 CN CNB988066289A patent/CN1145486C/zh not_active Expired - Fee Related
- 1998-07-01 PT PT98940152T patent/PT999841E/pt unknown
- 1998-07-01 ID IDW991585A patent/ID24528A/id unknown
- 1998-07-01 EA EA199901100A patent/EA002174B1/ru not_active IP Right Cessation
- 1998-07-01 WO PCT/EP1998/004176 patent/WO1999001135A1/en not_active Application Discontinuation
- 1998-07-01 EP EP98940152A patent/EP0999841B1/en not_active Expired - Lifetime
- 1998-07-01 AT AT98940152T patent/ATE206921T1/de not_active IP Right Cessation
- 1998-07-01 US US09/402,239 patent/US6166025A/en not_active Expired - Fee Related
- 1998-07-01 IL IL13320698A patent/IL133206A0/xx unknown
- 1998-07-01 JP JP50638199A patent/JP3350061B2/ja not_active Expired - Fee Related
- 1998-07-01 SI SI9830068T patent/SI0999841T1/xx unknown
- 1998-07-01 BR BR9810658-9A patent/BR9810658A/pt not_active Application Discontinuation
- 1998-07-01 NZ NZ501419A patent/NZ501419A/xx unknown
- 1998-07-01 PL PL98337803A patent/PL337803A1/xx unknown
-
1999
- 1999-11-30 BG BG103930A patent/BG103930A/xx unknown
- 1999-11-30 IS IS5283A patent/IS5283A/is unknown
- 1999-12-01 NO NO19995887A patent/NO312993B1/no unknown
- 1999-12-03 OA OA9900271A patent/OA11227A/en unknown
- 1999-12-30 HR HR970276A patent/HRP990416B1/xx not_active IP Right Cessation
-
2001
- 2001-01-05 HK HK01100144A patent/HK1029282A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
OA11227A (en) | Pharmaceutical compositions containing eletriptan hemisulphate and caffeine | |
RU2762725C2 (ru) | Композиции, содержащие триптановые соединения | |
BE1005085A3 (fr) | Medicaments. | |
AU2020220146B2 (en) | Ophthalmic compositions | |
HU199678B (en) | Process for producing aerosols containing nitroglicerol | |
US20050147564A1 (en) | Inhalable formulation of a solution containing a tiotropium salt | |
JP2008512428A (ja) | シクレソニドとSykインヒビターとの組合せ物並びにその使用方法 | |
US5169849A (en) | Nasal pharmaceutical compositions | |
DK1809293T3 (en) | An aerosol formulation for inhalation of beta-agonists. | |
US6007834A (en) | Nasal melatonin composition | |
GB2162745A (en) | Nasal compositions | |
AU743492B2 (en) | New formulation for the oromucosal, in particular pernasal, route | |
AP1100A (en) | Pharaceutical compositions containing eletriptan hemisulphate. | |
JP3498041B2 (ja) | プラルモレリン含有点鼻用製剤 | |
GB2114001A (en) | Nasal pharmaceutical compositions | |
MXPA99011299A (en) | Pharmaceutical compositions containing eletriptan hemisulphate and caffeine | |
CA1197783A (en) | Nasal pharmaceutical compositions | |
CZ466099A3 (cs) | Farmaceutické kompozice obsahující elektriptanhemisulfat a kofein | |
TWI221769B (en) | Pharmaceutical compositions containing eletriptan hemisulphate | |
JPH02286618A (ja) | フイゾスチグミンおよびアレコリンの鼻内投与用製剤 | |
EP0477251A1 (en) | Intranasal administration of 3,3-disubstituted indolines |